Its dual GLP-1 and GIP receptor activation produced a 20.9% average body weight reduction at 72 weeks in the SURMOUNT-1 trial, and more recent SURMOUNT-5 head-to-head data confirmed its superiority over Semaglutide
At week 52, the difference in HbA 1c reduction from baseline between TRESIBA and insulin glargine U-100 was 0.09% with a 95% confidence interval of [0.04%
Liraglutide, semaglutide and dulaglutide have demonstrated cardiovascular benefits, and Wegovy recently added to this evidence base: in the SELECT trial, patients on Wegovy had a 20% lower incidence of heart attack, stroke or death from heart disease compared to those on a placebo
A healthy, unstressed cell maintains a vast majority of its glutathione pool in the reduced state, typically sustaining a GSH-to-GSSG ratio of greater than 10:1, and often up to 100:1 in the cytosol
Read more 69 people found this helpful Advait Kapoor love the refreshed vibe